down arrow

AlloVir, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0198181036
USD
5.92
0.45 (8.23%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.425.96

52 Week

2.1412.90
Valuation
Technical
Day's Volume

CASH

65.47 k

Shareholding (Mar 2025)

FII

1.94%

Held by 45 FIIs

DII

24.53%

Held by 7 DIIs

Promoter

68.12%

How big is AlloVir, Inc.?

22-Jun-2025

As of Jun 18, AlloVir, Inc. has a market capitalization of 47.88 million and reported net sales of 0.00 million with a net profit of -38.68 million for the latest four quarters. Shareholder's funds are 113.31 million, and total assets amount to 118.55 million.

As of Jun 18, AlloVir, Inc. has a market capitalization of 47.88 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -38.68 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 113.31 million and total assets amounting to 118.55 million.

Read More

What does AlloVir, Inc. do?

22-Jun-2025

AlloVir, Inc. is a late clinical-stage cell therapy company focused on developing allogeneic T cell therapies for viral diseases, with a market cap of approximately $47.88 million and a net profit of -$10 million as of March 2025. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.

Overview: <BR>AlloVir, Inc. is a late clinical-stage cell therapy company engaged in developing allogeneic T cell therapies to treat and prevent viral diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 47.88 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.58 <BR>Return on Equity: -61.61% <BR>Price to Book: 0.75<BR><BR>Contact Details: <BR>Address: 139 Main Street, Suite 500, Suite 1274, CAMBRIDGE MA: 02142 <BR>Tel: 1 617 4332605 <BR>Fax: 1 302 6555049 <BR>Website: https://www.allovir.com

Read More

Who are in the management team of AlloVir, Inc.?

22-Jun-2025

As of March 2022, the management team of AlloVir, Inc. includes CEO David Hallal, President and CFO Vikas Sinha, and several directors: Juan Vera, Jeffrey Bornstein, Diana Brainard, Malcolm Brenner, and Ansbert Gadicke. They oversee the company's strategic direction and operations.

As of March 2022, the management team of AlloVir, Inc. includes the following individuals:<BR><BR>- Mr. David Hallal, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Vikas Sinha, who holds the positions of President, Chief Financial Officer, and Director.<BR>- Dr. Juan Vera, who is a Director.<BR>- Mr. Jeffrey Bornstein, who is an Independent Director.<BR>- Dr. Diana Brainard, who is also an Independent Director.<BR>- Mr. Malcolm Brenner, who serves as an Independent Director.<BR>- Dr. Ansbert Gadicke, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is AlloVir, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, AlloVir, Inc. has a neutral technical trend with mixed indicators, showing a short-term gain of 2.57% but a significant 1-year decline of 74.89%.

As of 4 September 2025, the technical trend for AlloVir, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators. The weekly MACD and Dow Theory are mildly bullish, while the weekly RSI is bearish. Moving averages are mildly bearish on a daily basis. The stock has shown strong short-term performance with a 1-week return of 2.57% compared to the S&P 500's 1.05%, but it remains significantly down over longer periods, with a 1-year return of -74.89% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 48 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.66

stock-summary
Return on Equity

-84.98%

stock-summary
Price to Book

0.90

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
29.54%
0%
29.54%
6 Months
92.21%
0%
92.21%
1 Year
-47.57%
0%
-47.57%
2 Years
-86.93%
0%
-86.93%
3 Years
-23.81%
0%
-23.81%
4 Years
-98.53%
0%
-98.53%
5 Years
-99.42%
0%
-99.42%

AlloVir, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is AlloVir, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for AlloVir, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed indicators. The weekly MACD and Dow Theory are mildly bullish, while the weekly RSI is bearish. Moving averages are mildly bearish on a daily basis. The stock has shown strong short-term performance with a 1-week return of 2.57% compared to the S&P 500's 1.05%, but it remains significantly down over longer periods, with a 1-year return of -74.89% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-4.24%
EBIT to Interest (avg)
-98.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.58
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.36%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.97
EV to EBIT
0.92
EV to EBITDA
0.92
EV to Capital Employed
1.06
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
115.33%
ROE (Latest)
-61.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 27 Schemes (5.41%)

Foreign Institutions

Held by 45 Foreign Institutions (1.94%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -86.89% vs 86.53% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.30",
          "val2": "-7.30",
          "chgp": "-68.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.40",
          "val2": "-6.10",
          "chgp": "-86.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 69.12% vs -12.86% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-55.30",
          "val2": "-180.90",
          "chgp": "69.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.20",
          "val2": "-18.60",
          "chgp": "45.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-58.80",
          "val2": "-190.40",
          "chgp": "69.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.30
-7.30
-68.49%
Interest
0.00
0.00
Exceptional Items
0.00
-0.50
100.00%
Consolidate Net Profit
-11.40
-6.10
-86.89%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -86.89% vs 86.53% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-55.30
-180.90
69.43%
Interest
0.00
0.00
Exceptional Items
-10.20
-18.60
45.16%
Consolidate Net Profit
-58.80
-190.40
69.12%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 69.12% vs -12.86% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About AlloVir, Inc. stock-summary
stock-summary
AlloVir, Inc.
Pharmaceuticals & Biotechnology
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. The Company’s product pipeline includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV) adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus six (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
Company Coordinates stock-summary
Company Details
139 Main Street, Suite 500, Suite 1274 , CAMBRIDGE MA : 02142
stock-summary
Tel: 1 617 4332605
stock-summary
https://www.allovir.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."